t
On 14 March 2025, 516,368 ordinary shares in Convatec Group Plc vested for Chief Financial Officer Jonny Mason under the company's Long Term Incentive Plan. Following this, on 18 March 2025, Mr. Mason sold 239,778 shares at £2.599537 each to satisfy income tax and National Insurance liabilities.
| Date | 18 Mar 2025 |
| Time | 17:51:23 |
| Category | Director/PDMR dealings |
| ID | 1936B |
18 March 2025
Convatec Group Plc
("Convatec" or "the Company")
Director/ PDMR Shareholding
The Company has been notified of the following transactions in relation to Persons Discharging Managerial Responsibility ("PDMR") in respect of ordinary shares of 10 pence each in the Company ("Shares").
Vesting of Awards under the Company's Long Term Incentive Plan ("LTIP")
On 14 March 2025, conditional share awards granted to Jonny Mason, Chief Financial Officer in 2022 under the LTIP in the form of Performance Share Awards ("PSA") vested and on 18 March 2025, shares were sold to satisfy income tax and National Insurance ("NI") liabilities:
|
Shares vested |
Shares sold to satisfy income tax & NI liabilities |
Share price |
Total shares acquired |
|
516,368
|
239,778 |
£2.599537 |
276,590 |
NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM
|
1
|
Details of the person discharging managerial responsibilities / person closely associated |
|||||
|
a)
|
Name
|
Jonny Mason |
||||
|
2
|
Reason for the notification
|
|||||
|
a)
|
Position/status
|
Chief Financial Officer and PDMR |
||||
|
b)
|
Initial notification /Amendment
|
Initial Notification |
||||
|
3
|
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
|||||
|
a)
|
Name
|
Convatec Group Plc |
||||
|
b)
|
LEI
|
213800LS272L4FIDOH92 |
||||
|
4
|
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
|
|||||
|
a)
|
Description of the financial instrument, type of instrument |
Ordinary shares of 10p each in Convatec Group Plc |
||||
|
|
|
|||||
|
Identification code |
GB00BD3VFW73 |
|||||
|
|
|
|||||
|
b)
|
Nature of the transaction
|
Vesting of PSA under the LTIP.
|
||||
|
c) |
Price(s) and volume(s)
|
|
||||
|
d)
|
Aggregated information |
|
||||
|
|
|
|||||
|
- Aggregated volume |
N/A - single transaction |
|||||
|
|
|
|||||
|
- Price |
|
|||||
|
|
|
|||||
|
e)
|
Date of the transaction
|
14 March 2025 |
||||
|
f)
|
Place of the transaction
|
Outside a trading venue |
||||
|
4
|
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
|
|||||
|
a)
|
Description of the financial instrument, type of instrument |
Ordinary shares of 10p each in Convatec Group Plc |
||||
|
|
|
|||||
|
Identification code |
GB00BD3VFW73 |
|||||
|
|
|
|||||
|
b)
|
Nature of the transaction
|
Immediate sale of shares awarded under the LTIP to cover tax and national insurance liabilities. |
||||
|
c) |
Price(s) and volume(s)
|
|
||||
|
d)
|
Aggregated information |
|
||||
|
|
|
|||||
|
- Aggregated volume |
N/A - single transaction |
|||||
|
|
|
|||||
|
- Price |
|
|||||
|
|
|
|||||
|
e)
|
Date of the transaction
|
18 March 2025 |
||||
|
f)
|
Place of the transaction
|
London Stock Exchange |
||||
Enquiries
James Kerton Company Secretary
Tel: +44 (7827) 036059
Email: [email protected]
Convatec Group Plc's LEI code is 213800LS272L4FIDOH92
Classification: 2.2 Information disclosed under article 19 of the Market Abuse Regulation
About Convatec
Pioneering trusted medical solutions to improve the lives we touch: Convatec is a global medical products and technologies company, focused on solutions for the management of chronic conditions, with leading positions in Advanced Wound Care, Ostomy Care, Continence Care, and Infusion Care. With more than 10,000 colleagues, we provide our products and services in around 90 countries, united by a promise to be forever caring. Our solutions provide a range of benefits, from infection prevention and protection of at-risk skin, to improved patient outcomes and reduced care costs. Convatec's revenues in 2024 were over $2 billion. The company is a constituent of the FTSE 100 Index (LSE:CTEC). To learn more please visit http://www.convatecgroup.com